title: Isradipine in patients with acute ischaemic cerebral infarction. An overview of the ASCLEPIOS Programme.
abstract: Calcium-related mechanisms are an integral part of metabolic reactions during acute cerebral infarction. In an animal model of stroke, the calcium antagonist isradipine was shown to protect neurons against ischaemia. In order to improve the neurological and functional outcome of human stroke patients, a randomised, double-blind, placebo-controlled multicentre study was started in up to 600 patients with acute ischaemic brain infarction. Since early treatment is considered to be of great importance, patients must be recruited no more than 12 hours after stroke onset. Medical, ECG, laboratory, neurological and functional evaluations are conducted for up to 90 days after stroke.
authors: CNS Department, Clinical Research, Sandoz Pharma Ltd, Basle, Switzerland.
authors: A
authors: A
authors: Azcona
authors: X
authors: X
authors: Lataste
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D011725:Pyridines; D017275:Isradipine